Introduction
Breast cancer is the most common malignancy in women. Approximately 10-15% of patients are reported to have a family history of breast cancer 1 . Mutations in the two hereditary breast cancer genes BRCA1 and BRCA2, identified in the mid 90's [2] [3] [4] [5] , are responsible for 15-20% of familial cases 1 . Although more than a decade of research has significantly increased our knowledge on BRCA gene function, this has not yet led to specific guidelines for the treatment of hereditary breast cancer patients 6 . BRCA1 and BRCA2 play major roles in the error-free repair of DNA double strand breaks (DSBs) through the process of homologous recombination (HR) [7] [8] [9] . Breast and ovarian tumors in BRCA-mutation carriers are typically deficient for BRCA function due to loss of heterozygosity 10, 11 . This inspired researchers to exploit the DNA repair defects of BRCA-mutated tumors by treating them with DNA damaging agents that either directly or indirectly induce DSBs.
Two classes of drugs that recently gained momentum in the treatment of BRCA-associated patients are platinum based cross linking agents and inhibitors of poly-(ADPribose) polymerase (PARP) activity. Cisplatin and carboplatin mostly induce interand intrastrand cross-links, but processing of these lesions results in intermediates of which the resolution depends on intact HR. This is thought to explain the strong sensitivity of BRCA1-and BRCA2-deficient cells towards these drugs 12, 13 . PARP activity is necessary for efficient single strand break (SSB) repair by the base excision repair (BER) pathway. In the absence of PARP activity, these lesions are thought to be converted into DSBs when encountered by replication forks that are unable to proceed. Whereas wild-type cells can subsequently repair these DSBs by HR, BRCAdeficient cells will accumulate unrepaired DSBs or misrepaired lesions due to promiscuous activity of other repair pathways, ultimately leading to mitotic catastrophe. Indeed, small molecule inhibitors of PARP enzymatic activity have been shown to be highly toxic to BRCA-deficient cells 14, 15 .
Both platinum-based drugs and olaparib (AZD2281;KU-0059436), a PARP inhibitor recently shown to kill BRCA-deficient mouse mammary tumor cells 16 , are currently in phase II clinical trials in breast cancer patients 17 . While clinical trials usually take several years to complete, experimentation using animal models has already yielded several important insights. Atlhough BRCA1-deficient mammary tumors responded well when treated with cisplatin, carboplatin or olaparib 18, 19 , it seems unlikely that treatment with these drugs will prove to be the definitive solution for curing BRCA-deficient cancer patients. In the same studies, Rottenberg et al. found that tumors develop resistance against olaparib and that treating with platinum drugs does not fully eradicate the tumor. Even combination treatment resulted in tumor relapse, albeit with a longer latency 19 . Hence, there is a continuing need for new drugs or drug combinations that selectively kill BRCA-deficient tumor cells.
In this paper, we report the development of an in vitro high-throughput screening system to identify compounds with specific toxicity towards BRCA2-deficient cancer cells. We have used this system to probe a commercially available library of 1258 drugs with known pharmacological activity and found three alkylating agents specifically toxic to BRCA2-deficient cells. Both in vitro and in vivo validation experiments further confirmed the potential of these drugs to treat BRCA-deficient tumors. In vitro drug combination studies showed an increased clinical window when these three alkylators were combined with PARP inhibition. Besides offering a platform for the identification of novel lead compounds for treatment of BRCA related cancers, these results call for a re-evaluation of alkylating agents already used in the clinic but not for treating breast cancer patients. These data further legitimize the assessment of combination therapies of alkylators with PARP inhibitors.
Results

Reconstitution of BRCA2-deficient mouse mammary tumor cells
We previously isolated a set of BRCA2-proficient (KP) and BRCA2-deficient (KB2P) mouse mammary tumor cell lines with differential responses to several agents such as cisplatin and the PARP inhibitor olaparib 16 . These cell lines are not suitable to perform pharmaceutical screens, because many other mutations may account for any specific toxicity found. Reconstituting the BRCA2-deficient KB2P-1.21 and KB2P-3.4 cell lines, resulting in isogenic cell line pairs with differential BRCA2 functionality, should overcome this problem. However, artificial BRCA2 expression from cDNA constructs was shown to severely impair cell growth 20 . We therefore chose to reconstitute the complete Brca2 gene including its endogenous promoter by stable introduction of a BAC clone encompassing the mouse Brca2 locus. Both KB2P lines were reconstituted with an HSV-1 based Brca2 infectious BAC (iBAC) 21 , which led to reconstitution of full-length Brca2 expression as shown by RT-PCR analysis (KB2P3.4R3 and KB2P1.21R2, Figure 1A ). Array CGH analysis confirmed the isogenicity of the BRCA2-deficient cell lines and their reconstituted counterparts (Supplementary Figure 1) . Rescue of Rad51 colocalization with γH2A.X in γ-irradiated KB2P3.4R3 and KB2P1.21R2 cells showed that the reconstitution was functional ( Figure 1B A. Scatter-plot depicting differential toxicities of 97 compounds for which IC50s could be determined. On the x-axis, differential toxicity between BRCA2-proficient (KP) and BRCA2-deficient cells is depicted. The y-axis indicates differential toxicity between BRCA2-reconstituted (KB2P) and BRCA2-deficient cells. B. Cytotoxicity profiles of chlorambucil, nimustine and melphalan performed on the complete cell-line panel validate the alkylators picked up from the screen. C. Immunofluorescence of γH2A.X (green) and Rad51 (red) in the nucleus (blue) of cells exposed for 24 hours to the alkylators at indicated concentrations. Co-localization of γH2A.X and Rad51 indicates induction of recombinogenic lesions. maceutical screens, we performed growth inhibition assays for olaparib and cisplatin on the KB2P, KB2PR and KP cell lines (Figure 1C) . BRCA2 Reconstitution completely reversed sensitivity to these compounds to similar levels as in the BRCA2-proficient KP lines (KB2P1.21R2) or to even higher levels (KB2P3.4R3). This hyperresistance correlated with higher Brca2 expression levels in KB2P3.4R3 cells compared to KP control cells as measured by qRT-PCR (data not shown). Since the window of differential sensitivity appeared highest in the KB2P3.4/KB2P3.4R3 combination, we used this isogenic pair of cell lines to perform a high-throughput pharmacological screen.
As an independent control, we used the BRCA2-proficient KP3.33 cell line 16 .
A high throughput screen for compounds with specific cytotoxicity against BRCA2-deficient cells
Using a high-throughput robotic screening system, we exposed KP3.33, KB2P3.4 and KB2P3.4R3 cells to a library of clinically active compounds (LOPAC, Sigma) containing 1258 compounds. 97 Drugs had an IC50 <50µM in any of the cell lines used ( Figure  2A ). To determine the influence of BRCA2 expression on the IC50 values, a combined specificity index (CSI) was calculated by addition of the log10 differential IC50 values for KB2P3.4 vs. KB2P3.4R3 and KB2P3.4 vs. KP3.33, respectively (See Supplementary  Table 1 ). Carboplatin, which is currently used in clinical trials in BRCA-associated breast cancer patients, was the fifth best hit with an IC50 of 4.4µM in the KB2P3.4 cells, but with no significant growth inhibition in the BRCA2-proficient cells. Also the topoisomerase inhibitors camptothecin and ellipticine showed a considerable differential cytotoxicity. Inhibition of topoisomerase activity is known to result in DNA strand breaks, which could explain the activity of these drugs.
In vitro validation of compounds
Four compounds (chlorambucil, melphalan, nimustine, 2-Cyclooctyl-2-hydroxyethylamine (CONH)) reported an even higher CSI than carboplatin. Except for CONH, which did not validate in subsequent experiments (data not shown), these compounds were alkylating agents not currently part of the standard of care for treating breast cancer patients 22 . To further validate the efficacy of these drugs, we determined growth inhibition curves of freshly dissolved compounds on our complete panel of cell lines. Indeed, for all three alkylators, both BRCA2-deficient cell lines showed much greater sensitivity than the BRCA2 reconstituted and -proficient controls ( Figure 2B ). Immunofluorescent staining revealed clear co-localization of γH2A.X and Rad51 foci after treating KP3.33 cells for 24hrs with the alkylators at IC50 concentrations. This confirms that these drugs are capable of inducing recombinogenic DNA breaks, which are known substrates for BRCA2 function.
In vitro synergism between alkylators and PARP inhibitor olaparib
Combinations of the DNA cross-linker cisplatin with the PARP inhibitor olaparib were previously shown to synergistically inhibit the growth of BRCA2-deficient cancer cells 16 . We assessed drug interactions between olaparib and chlorambucil, melphalan or nimustine in our panel of cell lines by determining combination index values for a range of combined drug concentrations. The means of all combination indices (CIs) of two independent experiments were calculated and averaged ( proficient cell lines resulted in additive effects rather than synergistic interactions. Since drug synergism was thus found to be specific for BRCA2-deficient cells, combining these drugs could further increase an existing clinical window in patients with BRCA-deficient tumors. . Alkylators were administered only once, while olaparib was administered daily during 28 consecutive days. Tumor bearing animals that were left untreated had to be sacrificed after 1-2 weeks, when tumors reached a size of approx. 1500 mm 3 ( Figure 3A -E). Efficacy of PARP inhibition as an approach to target BRCA2-deficient tumor cell growth is clearly shown, although responses were heterogeneous and tumors progressed quite rapidly after initial response to olaparib ( Figure 3A ). On the contrary, treatment with a single dose of cisplatin or any of the alkylators invariably resulted in partial or even complete tumor remission ( Figure 3B -E). Relapses occurred, however, in all cisplatin and chlorambucil treated animals. All but one melphalan and all nimustine treated animals remained relapse free, however, for at least 40 days.
In vivo responses of orthotopically transplanted BRCA2-deficient mammary tumor cells
Treatment responses of allografted BRCA2-deficient mammary tumors
Allografting BRCA2-deficient mammary tumor cell lines into the mouse mammary fat pad constitutes an efficient way of determining targeted drug efficacy in vivo. The physiological relevant pharmacodynamic and pharmacokinetic properties of these animal models provide valuable information in addition to in vitro systems.
However, these tumor cells may still have undergone extensive selection during prolonged in vitro culture. This may be overcome by direct engraftment of tumor pieces into multiple syngeneic animals, resulting in secondary tumors strongly recapitulating the parental tumors 18 . Similar to these studies, we engrafted tissue pieces originating from 5 independent BRCA2 and p53-deficient mammary tumors from K14cre;Brca2 and even needed to be sacrificed before the end of the 28-day treatment schedule, other tumors showed a partial response (tumors 3 and 5) or even complete remission before eventual relapse (tumor 2). In line with the results of the cell line allografts, tumor grafts generally showed stronger responses to chlorambucil, melphalan and nimustine than to olaparib. Relapses nevertheless occurred in the majority of tumors. Combination treatments of alkylators with olaparib were therefore performed to investigate possible synergistic drug interactions in vivo ( Figure 5 ). In vivo synergy between cisplatin and olaparib seemed weak or absent. Chlorambucil, melphalan and nimustine showed heterogeneity with respect to synergy with olaparib, and their generally effective single-drug responses limited precise assessment of drug interactions in vivo. Nevertheless, significant survival increases were observed in several cases, justifying further investigation of potential synergy between these alkylators and olaparib.
Discussion
Knowledge of the role of BRCA1 and BRCA2 in DNA damage repair has greatly accumulated in recent years. It can be expected that this knowledge will ultimately translate into treatment protocols that discriminate between sporadic cancers and BRCAassociated or BRCA-like tumors. Indeed, clinical trials with conventional and novel anticancer drugs targeting homologous recombination deficiency (HRD) are currently ongoing 17 . Both approaches taken in these clinical studies -inhibition of BER by PARP inhibitors and DNA damage induction by platinum-based cross-linkers -are thought to induce DSBs in replicating cells 14, 15, 25 . It is unknown, however, whether these agents are the most suitable compounds to reach this goal. Ideally, HRD targeting compounds should generate lesions that are only toxic to HRD cells without inducing DNA damage toxic to normal cells.
To identify novel compounds with specific toxicity towards BRCA2-deficient cells, we have developed a discovery pipeline consisting of isogenic cell lines suitable for high throughput in vitro screening, as well as in vivo models for validation studies. We found that three alkylators, which are currently not used in the treatment of breast cancer patients, exert strong differential in vitro cytotoxicity against BRCA2-deficient mammary tumor cells versus isogenic BRCA2-proficient control cells. In vivo validation studies in mice engrafted with BR-CA2-deficient tumor cell lines or primary tumors showed very strong antitumoral activity of all three alkylators especially given the fact that these compounds were administered only once. The compounds are bifunctional alkylating agents, with melphalan and chlorambucil belonging to the class of nitrogen mustards and nimustine being a nitrosourea compound. Bifunctional alkylators create both inter-and intrastrand cross-links in double stranded DNA. Platinum compounds such as cisplatin and carboplatin have similar activity but are thought to be different from most bifunctional alkylators because they mainly produce intrastrand cross-links instead of interstrand cross-links 25, 26 . Intrastrand lesions are repaired by nucleotide excision repair (NER) 27 . Thus, the differential sensitivity of HR-deficient vs. HR-proficient cells towards platinum compounds may actually be explained by a minority of the lesions produced, with many intrastrand cross-links as 'collateral damage' . These intrastrand cross-links may be selectively toxic in some HRD tumors, but not in others. Besides its role in HR, BRCA1 is also involved in NER
28
. BRCA1-associated tumors may thus be sensitive to intrastrand cross linking agents. BRCA2, on the other hand, is not implicated in NER. Although p53 is involved in NER 29 and many BRCA2 tumors have TP53 mutations, also BRCA2 tumors exist that have wild-type TP53 (Holstege et al., Cancer Res., in press). Treating these HR-deficient but NER-proficient BRCA2-associated tumors with platinum compounds may thus prove to be suboptimal due to the specific spectrum of DNA adducts formed. In addition, resistance mechanisms may differ between platinum compounds and bifunctional alkylators.
The use of melphalan and chlorambucil in the treatment of breast cancer is not entirely new. Especially poorly differentiated tumors showed favorable response to single-agent melphalan therapy 30 . However, regimens using melphalan or chlorambucil did not perform any better than the standard of care combination treatment at the time, cyclophosphamide, methotrexate and 5-fluorouracil (CMF) 31, 32 , and these alkylators were therefore abandoned as treatment options. While nimustine is mainly used in Japan for the treatment of malignant glioma, we are not aware of any clinical trials with this compound in breast cancer patients. Related compounds such as BCNU (carmustine) and CCNU (lomustine) have been part of drug combinations used in several clinical trials. Interestingly, carmustine was part of the LOPAC library but did not result in significant toxicity in BRCA2-deficient KB2P3.4 cells, even at 10µM concentration.
Importantly, early clinical trials with melphalan, chlorambucil and nitrosoureas have only been carried out in cohorts of breast cancer patients not selected for certain molecular properties .Strong specific response in patients with HRD tumors may thus have been obscured by absence of response in the majority of (HR-proficient) patients. In light of the strong preclinical responses reported in this study, re-evaluation of 'classical' alkylators in HRD tumors should be considered. Apart from BRCA-associated hereditary breast cancers, hormone receptor-and HER2-negative sporadic breast tumors (so-called "triple negative" tumors) are also believed to harbor a considerable fraction of HRD tumors with BRCA-like characteristics [33] [34] [35] . Our results show that mammary tumor cells are sensitive to cisplatin or the PARP inhibitor olaparib in a BRCA2 dependent fashion, further supporting the rationale for ongoing clinical trials with these compounds. In addition to favorable single agent activity of olaparib against BRCA2-deficient mammary tumors, we also observe in vitro synergy between olaparib and the alkylators, specifically in BRCA2-deficient cells. In vivo experiments suggest that this synergy also exists in a subset of BRCA2-deficient mouse mammary tumors, call for further experimentation to confirm this and to stratify between tumors benefiting from combination therapy and those that do not. Combining olaparib with bifunctional alkylators may thus further increase the clinical window for the treatment of BRCA-deficient cancers.
We introduce here a cell-based screening and validation system for identification and preclinical in vitro and in vivo valida-tion of compounds with specific toxicity against mammary tumor cells with a defined genetic lesion, i.e. BRCA2 deficiency. Our strategy, based on isogenic pairs of tumor cell lines, is in principle applicable to other tumor suppressor genes, provided that the reconstitution does not affect proliferation and/or survival of tumor cells. Our results obtained with isogenic BRCA2-deficient and -proficient mammary tumor cell lines call for a re-evaluation of melphalan, chlorambucil and nimustine as single agents or in combination with PARP inhibitors, in the clinical management of BRCA2-deficient breast cancer.
Materials and Methods
Cell line culturing and BRCA2 reconstitution KP3.33, KP6.3, KB2P1.21 and KB2P3.4 mouse mammary tumor cell lines 16 were cultured at 37°C, 5% CO 2 , 3% O 2 in complete medium (CM, DMEM/F-12 (Life Technologies) supplemented with 10% FCS, 50 units/ml penicillin, 50 µg/ml streptomycin (Life Technologies), 5 µg/ml insulin (Sigma), 5 ng/ml epidermal growth factor (Life Technologies) and 5 ng/ml cholera toxin (Gentaur)). To reconstitute the BRCA2-deficient cell lines, HSV-1/EBV amplicons containing the complete mouse Brca2 gene were produced as described previously 21 . 40x Concentrated Brca2 iBACs were aliquoted and stored at -80°C until use. After overnight infection and subsequent 48hr recovery, Brca2 iBAC containing KB2P cells were selected with 400µg/ml hygromycin. RT-PCR and Rad51/γH2A.X co-localization experiments to validate functional BRCA2 reconstitution were performed as described 16 .
Growth inhibition assays
All single-drug in vitro experiments were performed in 96-well plates. Typically, 150 KP3.33, 100 KP6.3, 400 KB2P1.21, 400 KB2P1.21R2, 500 KB2P3.4 and 300 KB2P3.4R3 cells were plated in 160µl CM on day 0. On day 1, 40µl drug containing CM was added while maintaining DMSO concentrations similar in all wells and <0.4%. On day 5, cells were incubated with 10µl cell-titer blue (Promega) for 4 hours at 37°C. Fluorescence was measured at 590 nm using an Envision plate reader (Perkin Elmer). Values from triplicate measurements were averaged, corrected for background and normalized against values from DMSO only controls. IC50 Values were calculated using Matlab software, as described 16 . All drug interaction experiments were done with SRB assays, since these were less prone to signal variation, which is crucial to accurate determination of combination indices. Combination index values were determined as described 16 .
Screen set-up 10mM DMSO Stocks of the LOPAC1280 compound library (Sigma) were used to create 5mM and subsequent ten-fold dilutions in DMSO. Cells were seeded on day 0 in 384-well plates in 40µl CM. On day 1, 96-well plates were prepared with 100-fold diluted drugs in CM in columns 2-11. Columns 1 and 12 were used for DMSO-only negative controls and multiple olaparib concentrations as positive controls. Assay plates were supplied with 10µl diluted compound. On day 5, a 4-hour incubation with 20µl 8x diluted cell-titer blue was used to determine cell viability. Screening was done using five 10-fold concentration steps, ranging from 1nM to 10µM. Mean values of technical duplicates were standardized against DMSOonly controls in the same plate and IC50 values were calculated. When IC50 values were >50µM or when the maximum growth inhibition of any range did not exceed 25%, IC50s were arbitrarily set at 50µM.
In vivo validation studies
Chlorambucil (Sigma) was dissolved in 70% EtOH to 50mg/ml. Immediately prior to use, this stock was diluted 40x with 100mM
Phosphate buffer pH6.8. Melphalan (Alkeran®, GlaxoSmithKline) was reconstituted immediately before administration, according to manufacturer's protocol. 1 Gram nimustine hydrochloride (Sigma) was dissolved in 6.5ml DMSO and just before injection, diluted 25-fold with physiological salt solution. Cisplatin was obtained from (Mayne Pharma). Olaparib was kindly provided by KuDOS Pharmaceuticals
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. All drugs were injected intraperitoneally, except for cisplatin which was injected in the tail vein.
Since all cells and tumors were derived from mice with a mixed FVB and 129/Ola background, (FVB x 129/Ola) F1 hybrid females were used for all animal experiments reported in this paper. Maximum tolerable doses (MTDs) were determined in at least three animals for all three alkylators and cisplatin using a 20% weight loss as a toxicity threshold. The following MTDs were established: chlorambucil: 15mg/kg; melphalan: 7.5mg/kg; nimustine: 30mg/kg; cisplatin: 6mg/kg. Olaparib was administered at 100mg/kg, at which no toxicity was observed, but higher amounts would exceed the maximum of 1ml daily injection volume. No additional toxicity was observed for the combinations of nimustine, chlorambucil or cisplatin with olaparib. In a small subset of transplanted animals, however, the combination of melphalan and olaparib was much more toxic than either drug alone. Therefore, the melphalan dose was adjusted to 5mg/kg in this combination. For the tumor intervention studies, either 500.000 KB2P3.4 cells, or 1mm 
